Revolution Medicines Insider Kelsey Sells Shares, Exercises Options at $4.73

Rhea-AI Filing Summary

Insider transactions by Stephen Michael Kelsey at Revolution Medicines (RVMD) show option exercises and systematic sales under a 10b5-1 plan adopted February 28, 2025. On September 11 and September 15, 2025, the reporting person acquired stock options exercisable at $4.73 (100,000 and 25,000 options) and sold portions of common stock in multiple trades at weighted average sale prices reported as $43.5771, $44.4847, $45.9175 and $46.9302. The filing reports beneficial ownership of 289,414 shares of common stock (direct) following the transactions and includes restricted stock units of 94,426 within holdings. The transactions were executed pursuant to the 10b5-1 plan and were signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Transactions were executed under a 10b5-1 plan, indicating pre-established trading instructions (adopted February 28, 2025).
• Form 4 discloses weighted-average sale prices and price ranges and includes an attorney-in-fact signature, supporting disclosure completeness.

Negative

• Significant share sales occurred (total reported disposals: 44,059; 55,941; 23,682; 1,318 across listed trades), which reduce the reporting person’s direct holdings.
• Filing does not state the total number of shares sold aggregated across all price ranges beyond the line-item amounts and weighted averages (additional detail available only upon request as noted).

Insights

Securities Analyst

TL;DR: Insider sold shares under a 10b5-1 plan while retaining substantial direct holdings and option positions.

The Form 4 documents option-related acquisitions at an exercise price of $4.73 and multiple block sales at weighted average prices between $43.58 and $46.93. The sales were executed under a pre-established 10b5-1 plan, which can indicate rule-compliant, pre-planned monetization rather than ad hoc sales. Reported direct beneficial ownership after these transactions is 289,414 common shares and the filing discloses 94,426 restricted stock units included within ownership. For investors, the filing conveys liquidity activity by a senior executive (President, Research and Development) but does not by itself provide evidence of company performance or near-term material events.

Corporate Governance Expert

TL;DR: Transactions follow governance best practice by using a 10b5-1 plan; filings are properly disclosed with execution-price ranges noted.

The filing states the 10b5-1 trading plan adoption date and provides weighted-average sale prices plus execution-price ranges for the multiple trades, and includes an attorney-in-fact signature. This level of disclosure supports transparency and compliance with Section 16 reporting obligations. The filing does not reveal any changes to officer status or other governance actions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kelsey Stephen Michael

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		M(1)		100,000	A	$4.73	389,414(2)	D
Common Stock	09/11/2025		S(1)		44,059	D	$43.5771(3)	345,355(2)	D
Common Stock	09/11/2025		S(1)		55,941	D	$44.4847(4)	289,414(2)	D
Common Stock	09/15/2025		M(1)		25,000	A	$4.73	314,414(2)	D
Common Stock	09/15/2025		S(1)		23,682	D	$45.9175(5)	290,732(2)	D
Common Stock	09/15/2025		S(1)		1,318	D	$46.9302(6)	289,414(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.73	09/11/2025		M(1)			100,000	08/09/2023	08/08/2029	Common Stock	100,000	$0	55,055	D
Stock Option (Right to Buy)	$4.73	09/15/2025		M(1)			25,000	08/09/2023	08/08/2029	Common Stock	25,000	$0	30,055	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.

2. Includes 94,426 restricted stock units.

3. The transaction was executed in multiple trades in prices ranging from $43.12 to $44.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The transaction was executed in multiple trades in prices ranging from $44.12 to $44.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. The transaction was executed in multiple trades in prices ranging from $45.4650 to $46.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

6. The transaction was executed in multiple trades in prices ranging from $46.5450 to $47.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President, Research and Development

	/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RVMD insider Stephen Michael Kelsey do according to the Form 4?

He exercised stock options (rights to buy 100,000 and 25,000 shares at $4.73) and sold common stock in multiple trades on 09/11/2025 and 09/15/2025 under a 10b5-1 plan.

How many shares does the reporting person beneficially own after these transactions?

The filing reports 289,414 shares of common stock beneficially owned (direct) following the reported transactions.

Does the Form 4 disclose restricted stock units or other equity awards?

Yes. The filing states that the beneficial ownership figure includes 94,426 restricted stock units.

At what prices were the insider sales executed?

Weighted-average sale prices reported: $43.5771, $44.4847, $45.9175, and $46.9302; execution-price ranges for each grouped trade are provided in the footnotes.

Was the trading activity planned or ad hoc?

The transactions were made pursuant to a 10b5-1 trading plan adopted on February 28, 2025, per the filing.